Data gathered: November 30
AI Stock Analysis - Palisade Bio (PALI)
Analysis generated May 6, 2024. Powered by Chat GPT.
Palisade Bio is a biopharmaceutical company that operates primarily in the field of addressing acute and chronic gastrointestinal complications that affect millions of patients globally. It focuses on developing innovative treatments seeking to enhance the body's natural response to surgery and other stressful events. As an investment prospect, Palisade Bio stands in a unique position where the demand for healthcare solutions is on the rise due to aging populations and an increasing focus on health and wellness. Being part of a high-growth industry, this company may attract investors looking for exposure to the medical technology and biopharma sectors.
Stock Alerts - Palisade Bio (PALI)
 |
Palisade Bio | November 26 Price is up by 5% in the last 24h. |
|
Palisade Bio | November 22 Price is up by 7.4% in the last 24h. |
|
Palisade Bio | November 20 Price is up by 7% in the last 24h. |
|
Palisade Bio | November 19 Price is up by 5.4% in the last 24h. |
Alternative Data for Palisade Bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 71 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 54 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,686 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,275 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,916 | Sign up | Sign up | Sign up |
| Twitter Mentions | 10 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 15 | Sign up | Sign up | Sign up |
About Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
| Price | $2.46 |
| Target Price | Sign up |
| Volume | 35,090 |
| Market Cap | $3.7M |
| Year Range | $2.2 - $8.46 |
| Dividend Yield | 0% |
| PE Ratio | 0.02 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Brokers Issue Forecasts for Palisade Bio FY2024 EarningsNovember 25 - ETF Daily News |
 |
Head-To-Head Comparison: Palisade Bio (NASDAQ:PALI) & Immunocore (NASDAQ:IMCR)November 24 - ETF Daily News |
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)November 21 - GlobeNewswire |
|
|
Critical Analysis: Palisade Bio (NASDAQ:PALI) vs. Anavex Life Sciences (NASDAQ:AVXL)November 16 - ETF Daily News |
 |
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNovember 13 - Yahoo |
|
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108November 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1.5M | -1.5M | -3.5M | 0 | -2.324 |
| Q2 '24 | 0 | 1.6M | -1.6M | -4.1M | -4.2M | -3.320 |
| Q1 '24 | 0 | 8.2M | -8.2M | -3.5M | -3.7M | -4.590 |
| Q4 '23 | -250,000 | 1.6M | -1.6M | -3M | -3.3M | -6.450 |
| Q3 '23 | 300,000 | 1.7M | -1.7M | -3.6M | -3.8M | -0.440 |
Insider Transactions View All
| Williams Donald Allen filed to buy 1,000 shares at $4.9. May 29 '24 |
| Finley John David filed to buy 8,437 shares at $4.8. May 28 '24 |
| Finley John David filed to buy 84,649 shares at $0.5. February 7 '24 |
| Williams Donald Allen filed to buy 30,000 shares at $0.6. February 1 '24 |
| Finley John David filed to buy 74,649 shares at $0.6. February 1 '24 |
Similar companies
Read more about Palisade Bio (PALI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Palisade Bio?
The Market Cap of Palisade Bio is $3.7M.
What is Palisade Bio's PE Ratio?
As of today, Palisade Bio's PE (Price to Earnings) ratio is 0.02.
What is the current stock price of Palisade Bio?
Currently, the price of one share of Palisade Bio stock is $2.46.
How can I analyze the PALI stock price chart for investment decisions?
The PALI stock price chart above provides a comprehensive visual representation of Palisade Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Palisade Bio shares. Our platform offers an up-to-date PALI stock price chart, along with technical data analysis and alternative data insights.
Does PALI offer dividends to its shareholders?
As of our latest update, Palisade Bio (PALI) does not offer dividends to its shareholders. Investors interested in Palisade Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Palisade Bio?
Some of the similar stocks of Palisade Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.